March 28, 2017
Amryt kicks off third phase of skin disorder treatment AP101
Amryt has begun with “EASE”, the Phase 3 clinical trial of AP101, its lead drug candidate, which offers a potential treatment for a rare genetic skin disorder that causes fragile skin.